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Germ-line mutation of the NRAS gene may be responsible for
the development of juvenile myelomonocytic leukaemia
Juvenile myelomonocytic leukaemia (JMML) is a rare,
clonal myeloproliferative/myelodysplastic disorder of infancy,
accounting for 2–3% of haematological malignancies of
childhood and characterised by overproduction of myeloid-
monocytic cells that infiltrate haematopoietic and non-hae-
matopoietic tissues (Emanuel et al, 1996; Niemeyer et al,
1997). JMML patients present with monocytosis, often with
dysplastic features, leucocytosis, anaemia and thrombocyto-
penia; liver and, in particular, spleen enlargement, as well as
lymph-node and skin involvement, are common findings. The
clinical course of the disease is generally extremely aggressive,
the median survival time of patients who are not given
allogeneic hematopoietic stem cell transplantation (HSCT)
being less than 1 year (Niemeyer et al, 1997). Indeed, although
occasional long-term survivors without transplantation have
been reported (Niemeyer et al, 1997; Matsuda et al, 2007)
allogeneic HSCT is the only accepted curative therapy for this
disease (Locatelli et al, 2005).
Myeloid progenitors of patients with JMML show a
characteristic hypersensitivity to granulocyte-macrophage
colony stimulating factor (GM-CSF) (Emanuel et al, 1991,
1996). This hypersensitivity is due to abnormalities of the
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Summary
We report the case of a child with clinical and haematological features
indicative of juvenile myelomonocytic leukaemia (JMML). The patient
showed dysmorphic features: high forehead, bilateral epicanthal folds, long
eyebrows, low nasal bridge and slightly low-set ears. A 38G>A (G13D)
mutation in exon 1 of the NRAS gene was first demonstrated on peripheral
blood cells, and then confirmed on granulocyte-macrophage colony-forming
units. The same mutation was also found in buccal swab, hair bulbs,
endothelial cells, skin fibroblasts. This case suggests for the first time that
constitutional mutations of NRAS may be responsible for development of a
myeloproliferative/myelodysplastic disorder in children.
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RAS-RAF-MAP (mitogen-activated protein) kinase signalling
pathway, which is pathologically activated by mutations of
RAS, NF1 and PTPN11 genes. In detail, approximately 30–35%
of children affected by JMML show somatic mutations in
PTPN11, 25–30% in either NRAS or KRAS, another 10–15% of
children having a clinical diagnosis of neurofibromatosis type 1
(Flotho et al, 2007). The mutations involving these genes are,
usually, mutually exclusive.
We report the case of a child with haematological and
clinical features suggestive of JMML in whom a heterozygous
germ-line Gly13Asp activating-mutation of NRAS was present;
to the best of our knowledge this is the second reported case of
a NRAS germ-line mutation.
Case report and methods
A male infant developed fever and marked hepato-spleno-
megaly at 2 months of age. JMML was diagnosed at 7 months
of age, according to the European Working Group on
Myelodysplastic Syndrome in Childhood (EWOG-MDS) cri-
teria (Niemeyer et al, 1998), based on the presence of
leucocytosis (31 · 109/l), absolute monocytosis (4Æ8 · 109/l),
modest thrombocytopenia (130 · 109/l), less than 20% bone
marrow (BM) blasts, spontaneous growth of granulocyte-
macrophage colony-forming units (CFU-GM) from peripheral
blood (PB), and presence of a 38G>A (G13D) mutation in
exon 1 of NRAS. Myeloid and erythroid precursors were
evident on PB smear. The search for bcr/abl fusion transcript
was negative, and the karyotype on BM and PB cells was
normal (46, XY). A search for locating a suitable unrelated
donor was started and no cytotoxic therapy was administered.
At the last evaluation, when the patient was 37 months old,
the haematological and clinical situation was stable, with
absolute leucocyte, monocyte and platelet counts of 19 · 109/l,
1Æ7 · 109/l and 170 · 109/l, respectively. At that time, hepato-
splenomegaly persisted; the patient weighed 13Æ9 kg (25–50th
centile), height was 88 cm (5–10th centile), while head
circumference was 51 cm (75–90th centile). Both parents
showed height at the 25–50th centile and head circumference
above the 75th centile.
In addition to short stature and relative macrocephaly, the
patient showed some dysmorphic features (not present in the
parents) including a high forehead, bilateral epicanthal folds,
long eyebrows, low nasal bridge, slightly low-set ears and two
caf e`-au-lait spots. Echocardiography showed normal findings
in repeated controls. Overall General Quotient (G.Q. = 97Æ6),
as tested through the Griffith Development Scales, was within
normal limits, with lower scores on performance tasks:
locomotor 126; personal-social 114; hearing and language 84;
hand coordination 84; performance 68.
PB mononuclear cells (PBMC) were isolated by Ficoll-
hypaque (Lymphoprep, Nycomed Pharma AS, Oslo, Norway)
density gradient centrifugation by standard method. Some of the
PBMCs were used to generate an Epstein-Barr Virus-induced
B-lymphoblastoid cell line (B-LCL), phytohaemagglutinin
(PHA)-activated T-lymphoblastoid cells and endothelial
cells according to previously reported methods (Comoli et al,
2002).
Erythroid burst-forming units (BFU-E) and CFU-GM
derived colonies were grown in a classical clonogenic assay as
previously reported (Massa et al, 2005). Long term culture
initiating cells (LTC-IC) assays were performed as previously
described (Rocci et al, 2007). DNA was prepared using
QIAamp DNA Blood Mini kit (Qiagen, Hilden, Germany),
according to manufacturer’s instructions, from the following
sources: PBMC, buccal swab, hair bulbs, B-LCL, PHA-
activated T-lymphoblastoid cells, BFU-E, CFU-GM, LTC-IC,
endothelial cells and cultured skin fibroblasts.
Results and discussion
The patient showed clinical and haematological findings
indicative of JMML; the 38G>A (G13D) mutation in exon 1
of NRAS was first demonstrated in PBMC and then confirmed
in CFU-GM derived colonies. Mutation analysis was extended
to PTPN11 (exons 3 and 13) (Tartaglia et al, 2005), and KRAS
(exons 1 and 2) (Jongmans et al, 2005) with normal results.
The presence of dysmorphic features prompted us to extend
mutation analysis to the above-mentioned cell types. All DNA
sources examined consistently showed the presence of the
38G>A mutation (Fig 1A, B). Clonal subcultures from
cultured fibroblasts were started from 1 to 5 cells and all the
six clones examined demonstrated the presence of the
mutation. The polymerase chain reaction (PCR) product of
exon 1 from the original fibroblast culture was then cloned in
bacterial TOP10 competent cells (TA Cloning kit; Invitrogen,
Carlsbad, CA, USA); both wild type and mutated sequences
were observed (Fig 1C, D). These results clearly demonstrated
that the 38G>A mutation was a germ-line (constitutional)
mutation found in all patient’s cells examined and occurred
de novo, as it was not evidenced in the parents.
Acquired somatic mutations in PTPN11, NRAS, KRAS and
NF1 are associated with the development of JMML. Patients
with neurofibromatosis type 1 are prone to develop JMML if a
subsequent somatic inactivation of the remaining normal allele
leads to homozygous inactivation of both NF1 alleles. Some
patients with Noonan Syndrome (NS), a heterogenous
disorder defined by short stature, facial dysmorphia, cardiac
defects, skeletal defects, mental retardation and bleeding
diathesis (van der Burgt, 2007), carry constitutional mutations
of PTPN11 or KRAS, as well as of other genes, including SOS1
and RAF1. JMML or a JMML-like clinical picture showing
spontaneous remission, have been observed in NS (van der
Burgt, 2007; Flotho et al, 2007).
No germ-line mutation had been described for NRAS
until Oliveira et al (2007) described a 49-year-old male with
a clinical diagnosis of autoimmune lymphoproliferative
syndrome (ALPS) carrying a heterozygous, germ-line, G13D
activating mutation in NRAS. The patient showed a peculiar
defect in cytokine withdrawal-induced apoptosis due the
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NRAS mutation, but no data as to the presence of dysmorphic
features or as to abnormalities of neurological development
were provided. So far, our patient, who carries the same
mutation, has not shown any haematological alterations
related to ALPS, and the study of Fas-mediated apoptosis
gave normal results (data not shown).
Despite some minor but clearly evident dysmorphisms, our
child did not fit the criteria included in the most recent scoring
system for NS (van der Burgt, 2007). Moreover, it is
noteworthy that, while constitutional mutations of KRAS have
been reported in NS patients, no patient was found to carry
germ-line mutations of NRAS.
The constitutional mutation of NRAS found in our patient
was already reported to occur as a somatic mutation in
children with confirmed diagnosis of JMML (Matsuda et al,
2007; Flotho et al, 2008). We cannot exclude that some of
these patients apparently carrying the somatic mutation may
have a germ-line one. In any case, our patient provides
evidence that germ-line mutations may occur also for NRAS,
and that they may be associated with different haematological
disorders in children and adults. Our case also emphasises the
concept that an accurate search for dysmorphic features should
be performed in any patient showing clinical and haemato-
logical features suggestive of JMML, as an indication of the
presence of constitutional mutations.
Our patient has so far benefited from a stable haemato-
logical and clinical situation for more than 2 years after
diagnosis. This could be explained by the fact that he was
diagnosed below the age of 2 years, a variable associated with a
less aggressive course (Niemeyer et al, 1997) and a better
chance of benefiting from allogeneic HSCT (Locatelli et al,
2005). Some authors also suggested that patients with specific
RAS mutations may have spontaneously improving disease
(Matsuda et al, 2007), although other studies contradicted this
hypothesis (Flotho et al, 2008). We cannot exclude that also
germ-line mutations of NRAS per se may be associated with a
less aggressive course. If true, the intriguing question of why
the same mutation, either germ-line or somatically acquired, is
associated with different degrees of clinical severity, remains
open and should be addressed in further studies.
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